在心脏缩中,NLRX1通过STING减轻内分泌网膜压力
Keying Mi1, Xiaoyan Wang1, Chao Ma2
1Department of Cardiology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, People's Republic of China; JiNan Key Laboratory of Cardiovascular Disease, Jinan, China.
Biochimica et biophysica acta. Molecular cell research
|October 2, 2024
概括
NLRX1蛋白通过减少内细胞网膜应激来保护心脏缩. 它抑制酸化STING (p-STING) 和关键的压力标志物,为心脏病提供潜在的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 细胞应激反应的应激反应
- 具有天生的免疫力.
背景情况:
- 细胞内膜网膜 (ER) 的压力和亡驱动心脏缩.
- 类似NOD的受体NLRX1影响细胞过程,在心脏病中表现出潜在的作用.
- 在心脏缩期间ER压力中NLRX1的作用尚不清楚.
研究的目的:
- 调查NLRX1在ER压力诱导的心脏缩中的作用和机制.
- 为了确定NLRX1是否影响心脏缩模型中的STING通路.
主要方法:
- 采用了一种细胞模型,用于研究由 ангиотензин II (Ang II) 诱导的心脏缩.
- 评估了NLRX1,化STING (p-STING) 和ER压力标志物的表达水平 (ATF4,CHOP,PERK,IRE1,eIF2α).
- 研究了STING激动剂 (DMXAA) 对NLRX1的保护功能的影响.
主要成果:
- 在高性心脏和细胞中,NLRX1和p-STING被上调.
- 过度表达NLRX1降低了p-STING和ER压力标志物 (ATF4,CHOP,p-PERK/PERK,p-IRE1/IRE1,p-eIF2α/eIF2α) 的表达.
- 通过DMXAA减少了NLRX1的保护作用,这表明了STING通路的参与.
结论:
- 通过通过p-STING抑制PERK-eIF2α-ATF4-CHOP通路,NLRX1可以减轻Ang II治疗心肌细胞中的ER压力.
- NLRX1证明了对心脏缩发展的保护作用.
- 向NLRX1可能为心脏缩提供一种新的治疗策略.
相关概念视频
01:31Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
01:37The Unfolded Protein Response
4.5K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
2
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
2
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3